

USSN 09/699,923
Amendment After Final Rejection

Docket No. 2836-E

2. Amendments to the Claims

This listing of claims will replace all prior versions and listings of claims in the application:

Claims 1-14 (*Cancelled*)

Claim 15 (*Currently amended*) An *in vitro* method of preparing a dendritic cell population comprising the steps of:

- (a) contacting hematopoietic stem cells, or progenitor cells, or both with a growth factor or cytokine *in vitro*, wherein the growth factor or cytokine consists of flt3-ligand in an amount sufficient to generate a dendritic cell population;
- (b) exposing the dendritic cells to an antigen; and
- (c) allowing the dendritic cells to process and express the antigen.

Claim 16 (*Currently amended*) An *in vitro* method of preparing a dendritic cell population comprising the steps of:

- (a) contacting hematopoietic stem cells, or progenitor cells, or both with a growth factor or cytokine *in vitro*, wherein the growth factor or cytokine consists of flt3-ligand and GM-CSF in amounts sufficient to generate a dendritic cell population;
- (b) exposing the dendritic cells to an antigen; and
- (c) allowing the dendritic cells to process and express the antigen.

Claims 17-22 (*Cancelled*)

Claim 23 (*Previously presented*) The method according to claim 15 wherein the flt3-ligand is human flt3-ligand.

Claim 24 (*Previously presented*) The method according to claim 16 wherein the flt3-ligand is human flt3-ligand.

Claim 25 (*Previously presented*) The method according to claim 16 wherein the GM-CSF is human GM-CSF.

Claims 26-28. (*Cancelled*)

USSN 09/699,923
Amendment After Final Rejection

Docket No. 2836-E

Claim 29 (*Currently amended*) An *in vitro* method, comprising:
 (a) collecting hematopoietic stem cells, progenitor cells, or both;
 (b) of preparing a dendritic cell population, the method comprising
 contacting the hematopoietic stem or progenitor cells with a growth factor or
 cytokine *in vitro*, wherein the growth factor or cytokine consists of flt3-ligand;
 and
 (c) in an amount sufficient to generate a dendritic cell population, thereby
 driving the cells to differentiate into generating a the dendritic cell population.

Claims 30-35 (*Cancelled*)

Claim 36 (*Previously presented*) The method according to claim 29 wherein the
flt3-ligand is human flt3-ligand.

Claim 37 (*Cancelled*)

Claim 38 (*Currently amended*) The method of claims 15, 16, or 29, wherein the
hematopoietic stem cells, or progenitor cells, or both have been enriched for the
CD34+ phenotype.